54
Participants
Start Date
April 30, 2005
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Triamcinolone acetate
Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney
The University of Western Australia
OTHER
University of Melbourne
OTHER
Marsden Eye Specialists
OTHER
University of Sydney
OTHER